Pfizer and Moderna vaccines stop coronavirus variants. The efficacy of mRna vaccines is confirmed by studies while the spotlights are turned on, also in Italy, on the Indian variant of the covid. PFIZER Two doses of Pfizer / BioNTech’s Covid vaccine provide over 95% protection from infection, hospitalization, serious illness and death, even among the elderly and at a stage where the English variant of the coronavirus Sars-CoV-2 ( B.1.1.7) was the dominant strain. This is what emerges from the first observational evaluation at national level of the efficacy of the product, carried out in Israel and published in ‘The Lancet’. The analysis shows “the public health benefits” of a national vaccination program that in Israel is found to be “the key factor in the decline of infections”. While the results are encouraging, the authors point out that a number of open challenges remain for pandemic control. The first is that the duration of immunity to Covid-19 remains “currently unknown”, and then there is the risk “that new variants resistant to vaccines will emerge in the future”. In addition, achieving herd immunity “will require a continuous increase in vaccination coverage around the world.” Early data nationwide also shows that a single dose of the vaccine has been associated with 58% protection against infection. 76% against hospitalization and 77% relative to the risk of death, and this – the experts highlight – underlines the importance of fully vaccinating adults. “As the country with the highest percentage of the population vaccinated against Covid, Israel offers a unique opportunity to determine the effectiveness of the vaccine in the real world and observe the wider effects of the vaccination program on public health,” notes the author. Lead of the analysis, Sharon Alroy-Preis, of the Israeli Ministry of Health. So far, no estimates of the efficacy of two doses of the vaccine were available for some key findings including efficacy among the elderly, the authors note. The observations that emerge “offer real hope that vaccination will eventually allow us to control the pandemic,” Alroy-Preis points out. The data used are those of national pandemic surveillance recorded by the Israeli Ministry of Health. The mean follow-up time for people who received two doses was 48 days. A nationwide impact assessment of the vaccination program on public health was also conducted, in terms of Covid cases. Pfizer / BioNTech vaccinations started in Israel amid a wave of infections that led to a national lockdown on December 27th. Daily infections peaked at 10,213 cases on January 20, 2021 and the lockdown was lifted on March 7, 2021. By April 3, 2021, 72% of people over 16 and 90% of those over 65 years old, she had received two doses. During the analysis period, there were 232,268 confirmed Covid infections in the country. The most popular strain was the Uk variant which accounted for 94.5% of the samples tested through the swab service. Two thirds of the cases involved people over the age of 16 (66.6%) and there were 7,694 hospitalizations, of which 4,481 serious and 188 critical, and 1,113 deaths. 7 days after the second dose, among the over 16 protection from infection was 95.3%, 96-97% against death, 97% and 91.5% against symptomatic and asymptomatic infections, respectively. The vaccine was also very effective in preventing hospital admissions and severe illness, providing 97.2% protection against general hospitalization. Within 14 days of vaccination, the protections conferred by the second dose increased to 96.5% against infection, 98% against hospitalization, and 98.1% against death. Protections among the elderly were as strong as those for young people, with analyzes indicating 94.1% against infections, 96.9% against hospitalization and 97% against death 7 days after received the second dose. Between the ages of 16 and 44, protection was 96.1% against infection, 98.1% against hospitalization, and 100% against death. In the country, daily infections continued to decline significantly as more people they received the vaccine. More rapid and faster declines have been observed in the over 65s, reflecting higher and earlier vaccination rates among the elderly, but similar patterns have been identified in all age groups confirming the impact and role of vaccination. although experts stress the importance of conducting further studies and evaluations for other variants and other population subgroups. MODERN A single booster dose of Moderna “increased neutralizing titers against Sars-CoV-2 and two variants of concern. (South African and Brazilian) in participants in previously vaccinated clinical trials “. The Moderna company announces it in a note. Moderna therefore reports the first results of an ongoing clinical study, in which it is testing a booster dose of 50 micrograms in individuals already vaccinated. Preliminary data show that this dose increased neutralizing antibody responses against the original virus, as well as against variants identified in South Africa and Brazil, and booster doses were ‘generally well tolerated’. “As we seek to defeat the ongoing pandemic, we remain proactively committed to following the evolution of the virus. We are encouraged by this new data, which bolsters our confidence that our recall strategy can be protective against these newly identified variants.” , explained Stéphane Bancel, CEO of Moderna. “The strong and rapid push of securities to levels above primary vaccination also clearly demonstrates the ability of mRna-1273 to induce immune memory – he continued – Our mRna platform allows rapid design vaccine candidates incorporating key mutations of the virus, potentially allowing for faster development of future alternative vaccines coupled with the variants, should they be needed. “” We would be delighted to be able to share data on our multivalent booster candidate, mRna-1273.211, which combines mRna -1273 and mRna-1273.351 in a single vaccine, when available rtare all the necessary updates to our Covid-19 vaccine to control the pandemic “, concluded Bancel.